ANAGENICS LIMITED — Director's Dealing 2013

Nov 24, 2013

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	Cellmid Limited
ABN	69 111 304 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	Ms Maria Halasz
Date of last notice	04 July 2013

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	A) Direct
	B) Indirect
	C) Indirect
Nature of indirect interest	)dA) Maria Halasz
(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	B) Direct Capital Pty Ltd – entitycontrolled by Director as Trustee for the
	Halasz Family Retirement Fund
	C) Direct Capital Group Pty Ltd – entity
	controlled bythe Director
Date of change	A) 25 November 2013
	C)25 November 2013
No. of securities held prior to change	A) 1,050,000 fully paid ordinary shares
	B) 5,700,000 fully paid ordinary shares
	7,000,000 unlisted opts exp 20 Nov 2014 ex
	price $0.056
	1,362,625 listed opts exp 23 Oct 2016 ex
	price $0.034
	C) 5,000,000 unlisted opts exp 15 June 2017
	ex price $0.032
Class	A) Fully paid ordinary shares
	C) Fully paid ordinary shares
Number acquired	A)12,000,000 fully paid ordinary shares
	C) 3,515,625 fully paid ordinary shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed	Nil
Value/ConsiderationNote: If consideration is non‐cash, provide details and estimatedvaluation	A) $0.03 per share (under Company’sEmployee Incentive Plan)C) 5% interest in Advangen InternationalPtyLtd(estimated value$90,000)
No. of securities held after change	A) 1,050,000 fully paid ordinary shares12,000,000fully paid ordinary sharesB) 5,700,000 fully paid ordinary shares7,000,000 unlisted opts exp 20 Nov 2014 exprice $0.0561,362,625 listed opts exp 23 Oct 2016 exprice $0.034C) 3,515,625 fully paid ordinary shares5,000,000 unlisted opts exp 15 June 2017 exprice $0.032
Nature of changeExample: on‐market trade, off‐market trade, exercise of options,issue of securities under dividend reinvestment plan, participation inbuy‐back	A) Issue of shares under Company’sEmployee Incentive PlanC) Issue of shares in consideration fortransfer of 5% interest in AdvangenInternational PtyLtd

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non‐cash, provide details and an estimated valuation Interest after change

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailedabove traded during a+closed period where prior writtenclearance was required?	No
If so, was prior written clearance provided to allow the tradeto proceed during this period?	N/A
If prior written clearance was provided, on what date was thisprovided?	N/A

25 November 2013

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 3